This trial is testing whether a PET scan using a tracer called [18F]F-AraG can help identify sites of Graft Versus Host Disease (GVHD) in patients who are likely to have the disease or are at high risk of developing it.
- Graft-versus-Host Disease
2 Primary · 1 Secondary · Reporting Duration: Duration of the follow up will extend to 6 months post final scan for all aGVHD subjects by chart review.
Awards & Highlights
3 Treatment Groups
Highly suspected to already have aGVHD
1 of 3
1 of 3
High risk of developing aGVHD
1 of 3
30 Total Participants · 3 Treatment Groups
Primary Treatment: [18F]F-Ara-G · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has [18F]F-Ara-G received authorization by the Food and Drug Administration?
"The [18F]F-Ara-G has been given an appraisal of 1, as the current trial is a Phase 1. This classification implies that there is only limited data proving its safety and efficacy." - Anonymous Online Contributor
What is the uppermost limit for enrollment in this experiment?
"Affirmative. Information hosted on clinicaltrials.gov reveals that this trial, which was originally posted in May of 2018, is looking for participants right now. The study will be recruiting 30 individuals at a single facility." - Anonymous Online Contributor
Is this trial currently in search of participants?
"Affirmative, according to clinicaltrials.gov this investigation is enrolling participants at present. It was first published on May 15th 2018 and modified most recently on March 7th 2022. 30 people need to be enlisted from one site for the study's success." - Anonymous Online Contributor